Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Diabetologia. 2010 Nov;53(11):2312-9. doi: 10.1007/s00125-010-1860-3. Epub 2010 Jul 28.
AIMS/HYPOTHESIS: The FinnDiane Study has reported that mortality in type 1 diabetes is not increased over a 7 year follow-up in the absence of renal disease (RD). Using the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study population (n = 658) of childhood-onset type 1 diabetes (age <17 years), the present study sought to replicate and expand these findings to a 20 year follow-up (as of 1 January 2008) and examine cause of death by renal status.
At baseline (1986-1988), mean age and duration of diabetes were 28 and 19 years, respectively. RD was defined as an albumin excretion rate ≥20 μg/min from multiple samples and grouped as microalbuminuria (MA; 20-200 μg/min), overt nephropathy (ON; >200 μg/min), or end stage renal disease (ESRD; dialysis or renal transplantation).
At baseline, 311 (47.3%) individuals had RD (MA 21.3%, ON 22.2% and ESRD 3.8%). During a median 20 year follow-up, there were 152 deaths (23.1%). Mortality was 6.2 (95% CI 5.2-7.2) times higher than expected, with standardised mortality ratios of 2.0 (1.2-2.8) for normoalbuminuria (NA); 6.4 (4.4-8.4) for MA; 12.5 (9.5-15.4) for ON; and 29.8 (16.8-42.9) for ESRD. Excluding those (n = 64) with NA who later progressed to RD, no significant excess mortality was observed in the remaining NA group (1.2, 0.5-1.9), whose deaths were largely unrelated to diabetes.
CONCLUSIONS/INTERPRETATION: These data confirm the importance of RD, including persistent microalbuminuria, as a marker of mortality risk and suggest that type 1 diabetes patients without renal disease achieve long-term survival comparable to the general population.
目的/假设:FinnDiane 研究报告称,1 型糖尿病患者在无肾脏疾病 (RD) 的情况下,7 年随访期间死亡率并未增加。本研究利用匹兹堡糖尿病并发症流行病学 (EDC) 研究人群(n=658)中儿童起病的 1 型糖尿病(年龄 <17 岁),旨在复制和扩展这些发现至 20 年随访(截至 2008 年 1 月 1 日),并根据肾脏状况检查死亡原因。
在基线时(1986-1988 年),平均年龄和糖尿病病程分别为 28 岁和 19 岁。RD 的定义为多次样本中白蛋白排泄率≥20μg/min,并分为微量白蛋白尿 (MA; 20-200μg/min)、显性肾病 (ON; >200μg/min) 或终末期肾病 (ESRD; 透析或肾移植)。
基线时,311 人(47.3%)存在 RD(MA 占 21.3%,ON 占 22.2%,ESRD 占 3.8%)。在中位 20 年随访期间,有 152 人死亡(23.1%)。死亡率比预期高 6.2 倍(95%CI 5.2-7.2),标准化死亡率比值分别为:正常白蛋白尿(NA)2.0(1.2-2.8);微量白蛋白尿(MA)6.4(4.4-8.4);显性肾病(ON)12.5(9.5-15.4);终末期肾病(ESRD)29.8(16.8-42.9)。排除那些随后进展为 RD 的 NA 患者(n=64)后,在剩余的 NA 组中未观察到显著的超额死亡率(1.2,0.5-1.9),这些死亡与糖尿病关系不大。
结论/解释:这些数据证实了 RD,包括持续微量白蛋白尿,作为死亡率风险的标志物的重要性,并表明无肾脏疾病的 1 型糖尿病患者实现了与一般人群相当的长期生存。